{"nctId":"NCT01910636","briefTitle":"Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection","startDateStruct":{"date":"2013-02"},"conditions":["Hepatitis C"],"count":153,"armGroups":[{"label":"Sofosbuvir+RBV 12 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: Sofosbuvir","Drug: RBV"]}],"interventions":[{"name":"Sofosbuvir","otherNames":["GS-7977","PSI-7977","Sovaldi®"]},{"name":"RBV","otherNames":["Copegus®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chronic genotype 2 HCV-infection\n* Male or female, age ≥ 20 years\n* Body weight ≥ 40 kg\n* HCV RNA ≥ 10,000 IU/mL at screening\n\nExclusion Criteria:\n\n* Current or prior history of clinically significant illness other than HCV\n* Pregnant or nursing female or male with pregnant female partner\n* Chronic liver disease of a non-HCV etiology\n* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"95.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)","description":"The percentage of participants permanently discontinuing any study drug due to an adverse event was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR 24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"95.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"95.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing Viral Breakthrough","description":"Viral breakthrough was defined as HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment, confirmed with 2 consecutive values (second confirmation value may have been posttreatment) or with a last available on-treatment measurement and no subsequent follow-up values.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing Viral Relapse","description":"Viral relapse was defined as having achieved undetectable HCV RNA levels (HCV RNA \\< LLOQ) at end of treatment, but did not achieve an SVR.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":153},"commonTop":["Nasopharyngitis","Anaemia","Headache","Malaise","Pruritus"]}}}